Is BDX a good stock to buy right now?

Based on our 6-factor quantitative model, BECTON DICKINSON & CO (BDX) receives a "Reduce" rating with a composite score of 38.5/100. It is ranked #2,918 out of 4,446 stocks. Key factor scores: Quality 46/100, Value 43/100, Momentum 26/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for BDX?

BECTON DICKINSON & CO (BDX) has a "Reduce" rating and 2-star score. The composite score of 38.5 ranks it #2,918 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is BDX in?

BECTON DICKINSON & CO operates in the Healthcare sector (Medical Equipment industry) with a market cap of $44.47 billion. It is classified as a large-cap stock.

Does BDX pay a dividend?

Yes, BDX pays a dividend with a current yield of 2.39%. For every $1,000 invested, you would receive approximately $23.90 in annual dividend income.

What is BDX's P/E ratio?

BDX has a trailing P/E ratio of 28.13x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is BDX?

BDX's quality factor score is 46/100. Gross margin: 44.9%. ROE: 6.2% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is BDX valued compared to peers?

BDX's value factor score is 43/100 (higher = cheaper). Key multiples: P/E 28.1x, EV/EBITDA 18.1x. Valuation is roughly in line with peers.

What is BDX's debt level?

BDX's debt-to-equity ratio is 117%. Sector average: 32%. Moderate leverage is normal for established companies.

BDX has a beta of 0.64, meaning it is less volatile than the market. Stability score: 74/100.

Does BDX have high short interest?

BDX's short interest factor score is 14/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

BDX Stock Analysis: Reduce (Score 38.5/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
BDX	-0.80%	-0.19%	-5.89%	-20.53%	-22.55%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-0.73%	-3.79%	-6.23%	-20.17%	-52.07%	-	-	-
Alpha vs Sector	+0.56%	-0.53%	-2.08%	-15.70%	-31.76%	-	-	-

Metric	BDX	Benchmark
P/E Ratio	28.1x	+19%
EV/EBITDA	18.1x	+186%
Price / Book	1.7x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
BDX BECTON DICKINSON & CO	39	46	43	26	28.1x	6.2%	44.9%	7.3%	5.3%	117.0x	$44.5B

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
Gross Margin %	0.4%	0.5%	0.5%	0.5%	0.4%	0.4%	0.5%	0.4%	0.5%	0.5%	0.5%
Operating Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%
FCF Margin %	-	-	-	15.5%	-	-	-	15.9%	13.7%	12.3%	15.1%
ROE %	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%	0.1%
ROA %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ROIC %	7.6%	1.7%	8.0%	4.3%	6.5%	7.1%	9.3%	3.0%	3.5%	2.9%	6.6%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Gross Margin %

0.4%

0.5%

0.4%

0.5%

0.4%

0.5%

Operating Margin %

0.1%

EBITDA Margin %

0.1%

0.2%

0.1%

0.2%

Net Margin %

0.1%

0.0%

0.1%

FCF Margin %

15.5%

15.9%

13.7%

12.3%

15.1%

ROE %

0.1%

0.0%

0.1%

0.0%

0.1%

0.0%

0.1%

ROA %

0.0%

ROIC %

7.6%

1.7%

8.0%

4.3%

6.5%

7.1%

9.3%

3.0%

3.5%

2.9%

6.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$21.2B	$21.8B	$20.2B	$19.4B	$18.9B	$20.2B	$17.1B	$17.3B	$16.0B	$12.1B	$12.5B	$10.3B
	—	$11.9B	—	$11.2B	$10.4B	$10.8B	—	—	—	—	—	—
	$9.5B	$9.9B	$9.1B	$8.2B	$8.5B	$9.4B	$7.6B	$8.3B	$7.3B	$5.9B	$6.0B	$4.7B
Gross Margin	44.9%	45.4%	45.2%	42.2%	44.9%	46.6%	42.3%	47.9%	45.5%	49.3%	48.0%	45.7%
	—	$5.3B	—	$4.7B	$4.7B	$4.9B	—	—	—	—	—	—
Research & Development	—	$1.3B	$1.2B	$1.2B	$1.3B	$1.3B	$1.1B	$1.1B	$1.0B	$774M	$828M	$632M
Depreciation	—	—	$2.3B	—	—	—	$2.2B	$2.3B	$2.0B	$1.1B	$1.1B	$891M
Total Operating Expenses	—	$7.3B	—	$6.1B	$6.2B	$6.6B	—	—	—	—	—	—
	$2.4B	$2.6B	$2.4B	$2.1B	$2.3B	$2.8B	$1.5B	$1.8B	$1.5B	$1.5B	$1.4B	$1.1B
EBIT	$2.4B	$2.6B	$2.4B	$2.1B	$2.3B	$2.8B	$1.5B	$1.8B	$1.5B	$1.5B	$1.4B	$1.1B
EBITDA	$2.4B	$2.6B	$4.7B	$2.1B	$2.3B	$2.8B	$3.0B	$4.1B	$3.8B	$2.5B	$2.6B	$2.0B
Operating Margin	11.4%	11.8%	11.9%	10.9%	12.1%	13.8%	5.7%	10.2%	9.4%	12.6%	11.5%	10.4%
EBITDA Margin	11.5%	11.8%	23.1%	10.9%	12.1%	13.8%	17.8%	23.5%	23.7%	20.7%	20.5%	19.3%
	—	$613M	$528M	$452M	$398M	$469M	$528M	$639M	$706M	$521M	$388M	$371M
	—	$1.9B	—	$1.7B	$1.8B	$2.2B	—	—	—	—	—	—
Income Tax Expense	—	$203M	$300M	$132M	$148M	$150M	$111M	-$57M	$862M	-$124M	$97M	$44M
	$1.6B	$1.7B	$1.7B	$1.5B	$1.8B	$2.1B	$874M	$1.2B	$311M	$1.1B	$976M	$695M
Net Margin	7.3%	7.7%	8.5%	7.7%	9.4%	10.3%	5.4%	7.1%	1.9%	9.1%	7.8%	6.8%
	$1.34	$5.83	$5.88	$4.97	$5.93	$6.92	$2.75	$4.01	$0.62	$4.70	$4.59	$3.43
Diluted EPS	$1.34	$5.82	$5.88	$4.94	$5.88	$6.85	$2.75	$4.01	$0.62	$4.70	$4.59	$3.43
Weighted Avg Basic	—	288M	—	286M	285M	289M	—	—	—	—	—	—
Weighted Avg Diluted	—	289M	—	288M	287M	292M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$21.2B

$21.8B

$20.2B

$19.4B

$18.9B

$20.2B

$17.1B

$17.3B

$16.0B

$12.1B

$12.5B

$10.3B

—

$11.9B

—

$11.2B

$10.4B

$10.8B

—

$9.5B

$9.9B

$9.1B

$8.2B

$8.5B

$9.4B

$7.6B

$8.3B

$7.3B

$5.9B

$6.0B

$4.7B

Gross Margin

44.9%

45.4%

45.2%

42.2%

44.9%

46.6%

42.3%

47.9%

45.5%

49.3%

48.0%

45.7%

—

$5.3B

—

$4.7B

$4.9B

—

Research & Development

—

$1.3B

$1.2B

$1.3B

$1.1B

$1.0B

$774M

$828M

$632M

Depreciation

—

$2.3B

—

$2.2B

$2.3B

$2.0B

$1.1B

$891M

Total Operating Expenses

—

$7.3B

—

$6.1B

$6.2B

$6.6B

—

$2.4B

$2.6B

$2.4B

$2.1B

$2.3B

$2.8B

$1.5B

$1.8B

$1.5B

$1.4B

$1.1B

EBIT

$2.4B

$2.6B

$2.4B

$2.1B

$2.3B

$2.8B

$1.5B

$1.8B

$1.5B

$1.4B

$1.1B

EBITDA

$2.4B

$2.6B

$4.7B

$2.1B

$2.3B

$2.8B

$3.0B

$4.1B

$3.8B

$2.5B

$2.6B

$2.0B

Operating Margin

11.4%

11.8%

11.9%

10.9%

12.1%

13.8%

5.7%

10.2%

9.4%

12.6%

11.5%

10.4%

EBITDA Margin

11.5%

11.8%

23.1%

10.9%

12.1%

13.8%

17.8%

23.5%

23.7%

20.7%

20.5%

19.3%

—

$613M

$528M

$452M

$398M

$469M

$528M

$639M

$706M

$521M

$388M

$371M

—

$1.9B

—

$1.7B

$1.8B

$2.2B

—

Income Tax Expense

—

$203M

$300M

$132M

$148M

$150M

$111M

-$57M

$862M

-$124M

$97M

$44M

$1.6B

$1.7B

$1.5B

$1.8B

$2.1B

$874M

$1.2B

$311M

$1.1B

$976M

$695M

Net Margin

7.3%

7.7%

8.5%

7.7%

9.4%

10.3%

5.4%

7.1%

1.9%

9.1%

7.8%

6.8%

$1.34

$5.83

$5.88

$4.97

$5.93

$6.92

$2.75

$4.01

$0.62

$4.70

$4.59

$3.43

Diluted EPS

$1.34

$5.82

$5.88

$4.94

$5.88

$6.85

$2.75

$4.01

$0.62

$4.70

$4.59

$3.43

Weighted Avg Basic

—

288M

—

286M

285M

289M

—

Weighted Avg Diluted

—

289M

—

288M

287M

292M

—

BECTON DICKINSON & CO (BDX) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does BECTON DICKINSON & CO Do?

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey. BECTON DICKINSON & CO (BDX) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Thomas E. Polen and employs approximately 77,000 people, headquartered in Franklin Lakes, New Jersey. With a market capitalization of $44.5B, BDX is one of the prominent companies in the Healthcare sector.

BECTON DICKINSON & CO (BDX) Stock Rating — Reduce (April 2026)

As of April 2026, BECTON DICKINSON & CO receives a Reduce rating with a composite score of 38.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BDX ranks #2,918 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BECTON DICKINSON & CO ranks #412 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BDX Stock Price and 52-Week Range

BECTON DICKINSON & CO (BDX) currently trades at $154.22. The stock lost $1.24 (0.8%) in the most recent trading session. The 52-week high for BDX is $233.07, which means the stock is currently trading -33.8% from its annual peak. The 52-week low is $156.35, putting the stock -1.4% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is BDX Overvalued or Undervalued? — Valuation Analysis

BECTON DICKINSON & CO (BDX) carries a value factor score of 43/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 28.13x, compared to the Healthcare sector average of 23.63x — a premium of 19%. The price-to-book ratio stands at 1.74x, versus the sector average of 2.75x. The price-to-sales ratio is 2.08x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BDX trades at 18.12x EV/EBITDA, versus 6.34x for the sector.

Overall, BDX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

BECTON DICKINSON & CO Profitability — ROE, Margins, and Quality Score

BECTON DICKINSON & CO (BDX) earns a quality factor score of 46/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 6.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 2.9% versus the sector average of -33.1%.

On a margin basis, BECTON DICKINSON & CO reports gross margins of 44.9%, compared to 71.5% for the sector. The operating margin is 11.4% (sector: -66.1%). Net profit margin stands at 7.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 5.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BDX Debt, Balance Sheet, and Financial Health

BECTON DICKINSON & CO has a debt-to-equity ratio of 117.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.05x, suggesting adequate working capital coverage.

BDX has a beta of 0.64, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for BECTON DICKINSON & CO is 74/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

BECTON DICKINSON & CO Revenue and Earnings History — Quarterly Trend

In TTM 2026, BECTON DICKINSON & CO reported revenue of $21.20B and earnings per share (EPS) of $1.34. Net income for the quarter was $1.57B. Gross margin was 44.9%. Operating income came in at $2.43B.

In Q1 2026, BECTON DICKINSON & CO reported revenue of $5.25B and earnings per share (EPS) of $1.34. Net income for the quarter was $382M. Gross margin was 45.9%. Revenue grew 1.6% year-over-year compared to Q1 2025. Operating income came in at $552M.

In FY 2025, BECTON DICKINSON & CO reported revenue of $21.84B and earnings per share (EPS) of $5.83. Net income for the quarter was $1.68B. Gross margin was 45.4%. Revenue grew 8.2% year-over-year compared to FY 2024. Operating income came in at $2.58B.

In Q3 2025, BECTON DICKINSON & CO reported revenue of $5.51B and earnings per share (EPS) of $2.00. Net income for the quarter was $574M. Gross margin was 47.8%. Revenue grew 10.4% year-over-year compared to Q3 2024. Operating income came in at $882M.

Over the past 8 quarters, BECTON DICKINSON & CO has demonstrated a growth trajectory, with revenue expanding from $4.99B to $21.20B. Investors analyzing BDX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BDX Dividend Yield and Income Analysis

BECTON DICKINSON & CO (BDX) currently pays a dividend yield of 2.4%. At this yield, a $10,000 investment in BDX stock would generate approximately $$239.00 in annual dividend income. The net margin of 7.3% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

BDX Momentum and Technical Analysis Profile

BECTON DICKINSON & CO (BDX) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 31/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BECTON DICKINSON & CO (BDX) ranks #412 out of 838 stocks based on the Blank Capital composite score. This places BDX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BDX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BDX vs S&P 500 (SPY) comparison to assess how BECTON DICKINSON & CO stacks up against the broader market across all factor dimensions.

BDX Next Earnings Date

No upcoming earnings date has been announced for BECTON DICKINSON & CO (BDX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BDX? — Investment Thesis Summary

The quantitative profile for BECTON DICKINSON & CO suggests caution. Momentum is weak at 26/100, a headwind for near-term performance. Low volatility (stability score 74/100) reduces downside risk.

In summary, BECTON DICKINSON & CO (BDX) earns a Reduce rating with a composite score of 38.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BDX stock.

Related Resources for BDX Investors

Explore more research and tools: BDX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BDX head-to-head with peers: BDX vs AZN, BDX vs SLGL, BDX vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

BD Files for CE Mark of Liverty TIPS Stent for Portal Hypertension

Becton Dickinson Trials Highlight Growth Potential In Interventional And Home Care

Q4 Earnings Highs And Lows: CONMED (NYSE:CNMD) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks

Market Crash: The Healthcare Stocks I'd Buy Without Hesitation

BD to Announce Financial Results for its Second Quarter of Fiscal 2026

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

BECTON DICKINSON & CO (BDX) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does BECTON DICKINSON & CO Do?

BECTON DICKINSON & CO (BDX) Stock Rating — Reduce (April 2026)

BDX Stock Price and 52-Week Range

Is BDX Overvalued or Undervalued? — Valuation Analysis

BECTON DICKINSON & CO Profitability — ROE, Margins, and Quality Score

BDX Debt, Balance Sheet, and Financial Health

BECTON DICKINSON & CO Revenue and Earnings History — Quarterly Trend

BDX Dividend Yield and Income Analysis

BDX Momentum and Technical Analysis Profile

BDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

BDX Next Earnings Date

Should You Buy BDX? — Investment Thesis Summary

Related Resources for BDX Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

BD Files for CE Mark of Liverty TIPS Stent for Portal Hypertension

Becton Dickinson Trials Highlight Growth Potential In Interventional And Home Care

Q4 Earnings Highs And Lows: CONMED (NYSE:CNMD) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks

Market Crash: The Healthcare Stocks I'd Buy Without Hesitation

BD to Announce Financial Results for its Second Quarter of Fiscal 2026